In the Asia-Pacific pharmaceutical industry, there were 11 private equity deals announced in Q1 2024, worth a total value of $1.3bn, according to GlobalData’s Deals Database. The $1.1bn Institutional Buy-out (IBO) SciClone Pharmaceuticals by GL Capital Group was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.

Smarter leaders trust GlobalData

In value terms, private equity deal activity in Asia-Pacific decreased by 48% in Q1 2024 compared with the previous quarter’s total of $2.5bn and fell by 0.8% as compared to Q1 2023. Related deal volume decreased by 15% in Q1 2024 versus the previous quarter and was 15% lower than in Q1 2023.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q1 2024 – Thematic Intelligence, buy the report here.

This content was updated on 23 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.